Our History

We are excited about the future and proud of our past.

Arrow Down Icon

“Science, science unite. Promise to protect mankind!”


Prof. Aina Muceniece (1924 – 2010)

Author of ECHO-7 virus discovery

1960


Scientists in the Institute of Microbiology and Virology of the Latvian Academy of Sciences discover that viruses recovered from the intestines of healthy children are capable of destroying tumors.

1960

1965


The Cancer Virotherapy Laboratory is established at the Institute to study this virus phenomenon further under the leadership of Aina Muceniece.

1965

1968


The Ministry of Health Protection (the competent regulatory authority) approves the start of RIGVIR® clinical trials in the 2nd Department of the Oncology Dispensary and the 18th Chemotherapy Department of the Pauls Stradiņš Clinical Hospital in Riga.

1968

1985


Extended RIGVIR® clinical trials start in three Riga hospitals: Latvian Oncology Center (the former Oncology Dispensary), the P. Stradiņš Clinical Hospital, Riga Stradiņš University Institute of Dentistry (at that time AML), and the Saratov Oncology Hospital (Russia). At that time the studies were, however, neither randomised nor double-blind. Over 700 patients are enrolled in these clinical trials until 1991.

1985

1987


Part of the multicenter and multinational Rigvir clinical trials also start at the All-Union Cancer Research Center in Moscow.

1987

1990


With the destabilization and collapse of Soviet Union the registration and research process of ECHO-7 virus and oncolytic virotherapy is interrupted and halted.

1990

2004


RIGVIR® is registered by the State Agency of Medicines of the Republic of Latvia, thus Rigvir becomes the first approved oncolytic virotherapy medication.

2004

2008


International Virotherapy Center is established in Riga, Latvia. Its mission is to provide virotherapy information for every cancer patient who wants it.

2008

2011


Oncolytic virotherapy with RIGVIR® is included in the list of reimbursable state-funded medical products in Latvia for skin melanoma patients.

2011

2015


Oncolytic virotherapy with RIGVIR® is included in the clinical guidelines of the National Health Service of Latvia entitled “Diagnostics, treatment and dynamic observation of skin cancer and melanoma”.

2015

2016


The first cancer virotherapy excellence center, the Global Virotherapy Cancer Clinic, is opened in Jūrmala, Latvia.

2016

2016


The RIGVIR® marketing authorization holder receives a grant from “Horizon 2020” to support activities for registration in the European Union.

2016

2017


RIGVIR® receives special recommendations for medication registration in EU from European Medicines agency (EMA).

2017

2017


RIGVIR® manufacturer receives intellectual property award “WIPO Enterprise Trophy”.

2017

2017


RIGVIR® manufacturer receives Seal of Excellence award given by European Commission.

2017

2018


Rigvir Group becomes a biotech company.

2018